Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 10, 2000 - Issue 8
Submit an article Journal homepage
37
Views
65
CrossRef citations to date
0
Altmetric
Review

Pharmacological approaches to the treatment of diabetic complications

Luca Costantino Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Campi 183, 41100 Modena, Italy. [email protected]
,
Giulio Rastelli Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Campi 183, 41100 Modena, Italy. [email protected]
,
Maria Cristina Gamberini Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Campi 183, 41100 Modena, Italy. [email protected]
&
Daniela Barlocco Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Campi 183, 41100 Modena, Italy. [email protected]
Pages 1245-1262 | Published online: 25 Feb 2005

Bibliography

  • THE DCCT RESEARCH GROUP: The effect of intensive diabetes treatment on the development and progres-sion of long-term complications in insulin-dependent diabetes mellitus: the diabetes control and complica-tions trial. N Engl. J. Med. (1993) 329:977–986.
  • TURNER NC, CLAPHAM JC: Insulin resistance, impaired glucose tolerance and non-insulin dependent diabetes, pathological mechanisms and treatment: current status and therapeutic possibilities. Prog. Drug Res. (1998) 51:33–94.
  • AMMON HPT, HARING HU, KELLERER M et al: Antidia-betic agents. Recent advances in their molecular and clinical pharmacology. Adv. Drug Res. (1996) 27:1–232.
  • HULIN B: New hypoglycaemic agents. Prog. Med. Chem.(1994) 31:1–58.
  • PORTE D, SCHWARTZ MW: Glucose complications: why is glucose potentially toxic? Science (1996) 272:699–700.
  • YABE-NISHIMURA C: Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. (1998) 50:21–33.
  • ••A review covering the most recent findings on ALR2 andglucose toxicity.
  • SIMA AAF, SUGIMOTO K: Experimental diabetic: an update. Diabetologia (1999) 42:773–788.
  • ••A complete review about the pathogenesis of diabeticneuropathy.
  • NISHIKAWA T, EDELSTEIN D, XUE LIANG DU et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404:787–790.
  • HOPFNER RL, GOPALAKRISHNAN V: Endothelin:emerging role in diabetic vascular complications. Diabetologia (1999) 42:1383–1394.
  • EVANS T, XENG DX, CHEN S, CHAKRABARTI S: Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes (2000) 49:662–666.
  • LAL S, SZWERGOLD BS, TAYLOR AH et al.: Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch. Biochem. Biophys. (1995) 318:191–199.
  • HAMADA Y, ARAKI N, KOH N, NAKAMURA J, HORIUCHI S, HOTTA N: Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Commun. (1996) 228:539–543.
  • ZYZAK DV, RICHARDSON JM, THORPE SR, BAYNES JW:Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch. Biochem. Biophys. (1995) 316:547–554.
  • HAMADA Y, ARAKI N, HORIUCHI S, HOTTA N: Role of polyol pathway in n on en zymatic glycation. Nephrol. Dialysis Transpl. (1996) 11 (Supp1.5):95–98.
  • TSUKUSHI S, KATZUSAKI T, AOYAMA I et al.: Increased erythrocyte 3-DG and AGES in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int. (1999) 55:1970–1976.
  • COSTANTINO L, RASTELLI G, CIGNARELLA G, VIANELLOP, BARLOCCO D: New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications. Exp. Opin. Ther. Patents (1997) 7:843–858.
  • SINGH SB, MALAMAS MS, HOHMAN TC, NILAKANTAN R, CARPER DA, KITCHEN D: Molecular modeling of the aldose reductase-inhibitor complex based on X-ray crystal structure and studies with single-site-directed mutants. J. Med. Chem. (2000) 43:1062–1070.
  • WILSON DK, TARLE I, PETRASH JM, QUIOCHO FA: Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor Zopolrestat. Proc. Nati Acad. Sci. USA (1993) 90:9847–9851.
  • URZHUMTSHEV A, TETE-FAVIER F, MITSCHLER A et al.: A specificity pocket inferred from the crystal structures of complexes of aldose reductase with the pharmaceu-tically important inhibitors Tolrestat and Sorbinil. Structure (1997) 5:601–612.
  • ASHIZAWA N, AOTSUKA T: Benzothiazole aldose inhibitors. Drugs Fut. (1998) 23:521–529.
  • ••Design of ARIs.
  • EGGLER JF, LARSON ER, LIPINSKI CA, MYLARI BL, URBAN: A perspective of aldose reductase inhibitors. Adv. Med. Chem. (1993) 2:197–246.
  • ••Development of hydantoins; discovery of Zopolrestat andrelated carboxylic acids.
  • SALAMAS MS, HOHMAN TC, MILLEN gentlemen: Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones:2[(4-bromo-2-fluoro-phenyl)methy1]-6-fluorospiro [iso quinoline-4 (1 H), 3'-pyrrolidine]-1,2',3,5t(211)-tetrone and congeners. 1. J. Med. Chem. (1994) 37:2043–2058.
  • MALAMAS MS, HOHMAN TC: N-substituted spir o succin mide, spiropyridazine, spiroazetidine and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2. J. Med. Chem. (1994) 37:2059–2070.
  • NEGORO T, MURATA M, UEDA S et al.: Novel, highlypotent aldose reductase inhibitors: R-(-)-2-(4-bromo-2-fluorobenzy1)-1,2,3,4-tetrahydropyrrolo [1,2-a] pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5-tetrone (AS-3201) and its congeners. J Med. Chem. (1998) 41:4118–4129.
  • TANIMOTO T, NISHIJAMA C: Molecular biology ofaldose reductase. Exp. Med. (1991) 9:541–547.
  • FEATHER MS, FLYNN TG, MUNRO KA, KUBIESKI TJ, WALTON DJ: Catalysis of reduction of carbohydrate 2-oxoaldehyde (osones) by mammalian aldose reductase and aldehyde reductase. Biochim. Biophys. Acta (1995) 1244:10–16.
  • RATTLIFF DM, VANDER JAGT DJ, EATON RP, VANDERJAGT DL: Increased levels on methylglyox al-metabolizing enzymes in mononuclear and polymor-phonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I and glyoxalase II- A clinical research study. J. Clin. Endocrinof Metab. (1996) 81:488–492.
  • VAN ZANDT MC, SIBLEY EO, COMBS KJ et al.: Design andsynthesis of novel inhibitors of aldose reductase for the treatment of diabetic complications. Proceedings of the 218th ACS National Meeting. New Orleans, USA (1999) MEDI 137.
  • WILLSON TM, BROWN PJ, STERNBACH DD, HENKE BR:The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43:527–550.
  • SARGES R, OATES PJ: Aldose reductase inhibitors:recent developments. Prog. Drug Res. (1993) 40:99–161.
  • NAKAO K, ASAO M., SHIRAI H et al.: Benzoxazoline andbenzimidazoline derivatives as novel aldose reductase inhibitors, Part 1: lead evolution. Med. Chem. Res. (1999) 9:621–630.
  • NAKAO K, ASAO M., SHIRAI H et al.: Benzoxazoline andbenzimidazoline derivatives as novel aldose reductase inhibitors, Part 2: lead optimization. Med. Chem. Res. (1999) 9:631–642.
  • MURATA M, FUJITANI B, MIZUTA H: Synthesis andaldose reductase inhibitory activity of a new series of 5 [[2-(omega-carboalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives. Eur. J. Med. Chem. (1999) 34:1061–1070.
  • FRESNEAU P, CUSSAC M, MORAND J, SZYMONSKI B, TRANQUI D, LECLERC G: Synthesis, activity and molecular modeling of new 2,4-dioxo-5-(naphtyl-methylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors. J Med. Chem. (1998) 41 :4706–4715.
  • Beilsteins Handbuch der Organischen Chemie 7, Band IV:759.
  • ROGUIAUX H, VAN ZANDT M, CHEVRIER B et al.: Bindingof aldose reductase inhibitors: correlation of crystallo-graphic and mass spectrometric studies. j Am. Soc. Mass Spectrom. (1999) 1 0 :635–647.
  • DONKOR IO, ABDEL-GHANY YS, KADOR PF, MIROGUCHI T, BARTOOSZKO-MALIK A, MILLER DD: Synthesis and biological activity of aldose reductase inhibitors with Michael acceptor substituents. Eur. Med. Chem. (1999) 34:235–243.
  • ARES JJ, KADOR PF, MILLER DD: Synthesis andbiological evaluation of irreversible inhibitors of aldose reductase. J Med. Chem. (1986) 29:2384–2389.
  • SAAB NH, DONKOR IO, RODRIGUEZ L, KADOR PF, MILLER DD: Phenylsulfonylnitrometanes as potent irreversible inhibitors of aldose reductase. Eur. J Med. Chem. (1999) 34:745–751.
  • SMAR MW, ARES JJ, NAKAYAMA T, ITABE H, KADOR PF,MILLER DD: Selective irreversible inhibitors of aldose reductase. J Med. Chem. (1992) 35:1117–1120.
  • PFEIFER MA, SCHUMER MP, GELBER DA: Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes (1997) 4 6 (Suppl. 2):S82–S89.
  • Zopthestat. Drugs Fut. (2000) 2 5 (1):123.
  • GREENE DA, SIMA AAF: Effect of aldose reductase inhibitors on the progression of nerve damage. Diabetic Med. (1993) 10 (Supp1.2):31S–32S.
  • CAMERON NE, COTTER MA, DINES KC, MAXFIELD EK, CAREY F, MIRRLEES DJ: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considera-tions and independence from a myo-inositol mechanism. Diabetologia (1994) 37:651–663.
  • TOMLINSON DR: Future prevention and treatment of diabetic neuropathy. Diabetes Metab. (1998) 24 (Suppl. 3):79–83.
  • MALIK RA: Pathology and pathogenesis of diabetic neuropathy. Diabetes Rev. (1999) 7:253–260.
  • CHAN NN, VALLANCE P, COLHUN HM: Nitric oxide and vascular responses in Type I diabetes. Diabetologia (2000) 43:137–147.
  • GRAIER WF, SIMECEK S, WASCHER TC, HOLZMANN S, KUKOVETZ WR, KOSTNER GM: The aldose reductase inhibitor, Zopolrestat, amplifies blood vessel relaxa-tion by inhibition of cGMP-specific phosphodies-terase. Diabetologia (1995) 38 (Supp1.1):Abstract 1008.
  • ASHIZAWA N, YOSHIDA M, SUGIYAMA Y et al: Effect of a novel aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpnj Pharmacol. (1997) 73:133–144.
  • COSTANTINO L, RASTELLI G, VIANELLO P, CIGNARELLAG, BARLOCCO D: Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med. Res. Rev. (1999) 19:3–23.
  • MALIK RA: Can diabetic neuropathy be prevented byACE inhibitors? Ann. Med. (2000) 32:1–5.
  • A53201. Drugs Fut. (2000) 25:131–136.
  • WILLIAMSON JR, CHANG K, FRANGOS M et al.: Hypergly-cemic pseudohypoxia and diabetic complications. Diabetes (1993) 42:801–813.
  • TILTON RG, CHANG K, NEYENGAARD JR, VAN DEN ENDEN M, IDO Y, WILLIAMSON JR: Inhibition of Sorbitol dehydrogenase. Effects on vascular and neural dysfunctions in sreptozotocin-induced diabetic rats. Diabetes (1995) 44:234–242.
  • •A review concerning the role of sorbitol dehydrogenase in mediating sorbitol pathway-linked neural and vascular dysfunction in rats with streptozocin-induced diabetes.
  • GEISEN K; UTZ R, GROTSCH H, LANG J, NIMMESGERN H:-accumulating pyrimidine derivatives. Arz. Forsch. Drug Res. (1994) 44:1032–1043.
  • OBROSOVA IG, FATHALLAH L, LANG HJ, GREENE DA: Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia (1999) 42:1187–1194.
  • BAYNES JW, THORPE SR: Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes (1999) 48:1–9.
  • FRIEDMAN EA: Advanced glycation end products and hyperglycemia in the pathogenesis of diabetic compli-cations. Diabetes Care (1999) 22 (Supp1.2):B65–B71.
  • ••A review concerning all the main pathways linking excessglucose to diabetic complications.
  • BROWNLEE M: Negative consequences of glycation. Metabolism (2000) 49 (Supp1.1) :9–13.
  • THORNALLEY PJ: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGES. Cell. Mol. Biol. (1998) 44:1013–1023.
  • TOMLINSON DR: Mitogen-activated protein kinases as glucose transducers for diabetic complications. (1999) 42:1271–1281.
  • TAGUCHI A, BLOOD DC, DEL TORO G et al.: Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases. Nature (2000) 405:354–360.
  • BONNARDEL-PHU E, WAUTIER JL, SCHMIDT AM et al: Acute modulation of albumin microvascular leakage by advanced glycation end products in microcircula-tion of diabetic rats in vivo. Diabetes (1999) 48:2052–2058.
  • RENARD C, CHAPPEY 0, WAUTIER MP et al: Recombi-nant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharmacol (1997) 52:54–62.
  • YAN SHI DU, ZHU H, ZHU A et al: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nature Med. (2000) 6:643–651.
  • COHEN MP, SHARMA K, JIN Y et al.: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J Clin. Invest. (1995) 95:2338–2345.
  • BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Arninoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 232:1629–1632.
  • BROWNLEE M: Glycation and diabetic complications.Diabetes (1994) 43:836–841.
  • KALIFAH RG, BAYNES JW, HUDSON BG: Arnadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. (1999) 257:251–258.
  • ABORDO EA, MINHAS HS, THORNALLEY PJ: Accumula-tion of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem. Pharmacol. (1999) 58:641–648.
  • THORNALLEY PJ: Kinetic and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions.. Pharmacol. (2000) 60:55–65.
  • LO TVV, SELWOOD T, THORNALLEY PJ: The reaction of methylglyoxal with aminog-uanidine under physio-logical conditions and prevention of methylglyoxal binding to plasma proteins. Biochem. Pharmacol (1994) 48:1865–1870.
  • NILLSON BO: Biological effects of aminog-uanidine: an update. Inflamm. Res. (1999) 48:509–515.
  • VASAN S, ZHANG X, ZHANG X et al.: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 382:275–278.
  • WOLFENBUTTEL BHR, BOULANGER CM, CRIJNS FRL etal: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. USA (1998) 95:4630–4634.
  • THORNALLEY PJ, MINHAS HS: Rapid hydrolysis and slow a,13-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol (1999) 57:303–307.
  • BOOTH AA, KHALIFAH RG, TODD P, HUDSON BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end products: comparison with aminog-uanidine. Biochem. Biophys. Res. Commun. (1996) 220:113–119.
  • BOOTH AA, KHALIFAH RG, TODD P, HUDSON BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem. (1997) 272:5430–5437.
  • EMILSSON H: Synthesis and antihypertensive activity of 5-substituted 4-amino-3-hydrazino-4H-1,2,4-triazoles and the corresponding 3-(2,6-dichloro-benzylidenehydrazino) derivatives. Acta Pharmaceu-tica Nordica (1989) 2:67–74.
  • KOKIAN M, MANJULA BN, EGAN JT: Chronic do sing with aminog-uanidine and novel advanced glycosilation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes (1996) 45:1694–1700.
  • NAKAMURA S, MAKITA Z, ISHIKAWA S et al: Progression of nephropathy in spontaneous diabetic rats is prevented by OBP-9195, a novel inhibitor of advanced glycation. Diabetes (1997) 46:895–899.
  • SHODA H, MIYATA S, LIU BF et al.: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology (1997) 138:1886–1892.
  • MUNCH G, TANELI Y, SCHRAVEN E et al: The cognition-enhancer drug tenilsetam is an inhibitor of protein cross-linking by advanced glycosylation. J. Neural Transm. Park Dis. Dement. Sect. (1994) 8:193–208.
  • RAHBAR S, YERNINI KK, SCOTT S, GONZALES N, LALEZARI I: Novel inhibitors of advanced glycation end products. Biochem. Biophys. Res. Commun. (1999) 262:651–656.
  • LALEZARI I, LALEZARI P: Synthesis and investigation of of 2-(4-(((arylamino)carbonyl)amino)-phenoxy)-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relation-ships. J. Med. Chem. (1989) 32:2352–2357.
  • GIUGLIANO D, CERIELLO A. PAOLISSO G: Oxidative and diabetic vascular complications. Diabetes Care (1996) 19:257–267.
  • •The possible links between hyperglycaemia-induced oxidative stress and diabetic complications are reviewed.
  • BROWNLEE M: Negative consequences of glycation. Metab. Clin. Exp. (2000) 49 (Suppl. 0:9–13.
  • FU MIN-XIN, WELLS-KNECHT KJ, BLACKLEDGE JA, LYONSTJ, THORPE SR, BAYNES JW: Glycation, glycoxidation and cross-linking of collagen by glucose. Diabetes (1994) 43:676–683.
  • LOW PA, NICKANDER KK, TRITSCHLER HJ: The roles ofoxidative stress and antioxidant treatment in experi-mental diabetic neuropathy. Diabetes (1997) 46 (Supp1.2):S38–542.
  • KUNISAKI M, BURSELL SE, UMEDA F, NAWATA H, KINGGL: Normalization of diacylglycerol-protein kinase C activation by Vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes (1994) 43:1372–1377.
  • KUNISAKI M, BURSELL SE, CLERMONT AC et al.: Vitamin Eprevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. J. Physiol. (1995) 2 6 9:E239–E246.
  • TASINATO A, BOSCOBOINIK D, BARTOLI GM, MARONI P,AZZI A: d-a-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with Protein kinase C inhibition and is independent of its antioxidant properties. Proc. Natl. Acad. Sci. USA (1995) 92 :12190–12194.
  • CERIELLO A: Oxidative stress and glycemic regulation. Metabolism (2000) 49 (Supp1.2):27–29.
  • MIDDLETON E, KANDASWAMI C: The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. In: The flavonoids. Advances in research since 1986. Harbornae JB (Ed.), Chapman and Hall, London, UK (1994):619–652.
  • BAYNES JW: Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 40:405–412.
  • ODETTI PR, BORGOGLIO A, DE PASCALE A, ROLANDI R, ADEZATI L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by am in o guan idin e and Rutin. Diabetes (1990) 39:796–801.
  • KEENOY BMY, VERTOMMEN J, DE LEEUW I: The effect of flavonoid treatment on the glycation and antioxidant status in Type I diabetic patients. Diabetes Nutr. Met. (1999) 12:256–263.
  • IDO Y, VINDIGNI A, VHANG K et al.: Prevention ofvascular and neural dysfunction in diabetic rats by C-peptide. Science (1997) 2 7 7:563–566.
  • JOHANSSON BL, SJOBERG S, WAHREN J: The influence ofhuman C-peptide on renal function and glucose utilization in Type I (insulin-dependent) diabetic patients. Diabetologia (1992) 35:121–128.
  • JOHANSSON BL, LINDE B, WAHREN J: Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of Type I (insulin-dependent) diabetic patients. Diabetologia (1992) 35:1151–1158.
  • JOHANSSON BL, BORG K, FERNQVIST-FORBES E, ODERGREN T, REMAHL S, WAHREN J: C-pep tide improves autonomic nerve function in patients with Type 1 diabetes. Diabetologia (1996) 39:687–695.
  • FORST T, PFUTZNER A, BEYER J, WAHREN J: New aspects on biological activity of C-peptide in IDDM patients. Exp. Clin. Endocrinol. Diabetes (1998) 106:270–276.
  • WAHREN J, EKBERG K, JOHANSSON J et al: Role of C-peptide in human physiology. Am. J. Physiol Endocrinol. Metab. (2000) 278:E759–768.
  • OHTOMO Y, APERIA A, SAHLGREN B, JOHANSSON BL, WAHREN J: C-peptide stimulates rat renal tubular Na±/K+ ATP-ase activity in synergism with neuropep-tide Y. Diabetologia (1996) 39:199–205.
  • KUNT T, SCHNEIDER S, PFUTZNER A et al.: The effect of human proinsulin C-peptide on erythrocyte deform-ability in patients with Type I diabetes mellitus. Diabetologia (1999) 42:465–471.
  • KUNT T, FORST T, CLOSS E et al.: Activation of endothe-lial nitric oxide synthase (eNOS) by C-peptide. Diabetologia (1998) 41 (Supp1.1) :A176 .
  • KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
  • MURRAY KJ, COATES WJ: Protein kinases and phosphatases: structural biology and synthetic inhibi-tors. Ann. Rep. Med. Chem. (1994) 29:255–264.
  • ISHII H, JIROUSEK MR, KOYA D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitors. Science (1996) 272:728–31.
  • JIROUSEK MR, GILLIG JR, GONZALEZ CM et al.: (S)-134(dimethylamino)methy11-10,11,14,15-tetra-hydr o-4,9:16,21 -dimeth en o-1 H,13H-dibenzo [e,k]pyrr olo [3,4-h][1,4,13]oxadiazacyclohexadecene-1,3-(2 dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med. Chem. (1996) 39:2664–2671.

Websites

  • Alteon Web page: http://www.alteonpharma.com/ (July 2000).
  • BioStratum Web page: http://www.biostratum.com/ (July 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.